Neuroleptic malignant syndrome after antipsychotic drug administration during benzodiazepine withdrawal.
Bobolakis
I
I
D000328:Adult; D000368:Aged; D014151:Anti-Anxiety Agents / Q000009:adverse effects*; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines; D001883:Borderline Personality Disorder / Q000175:diagnosis / Q000188:drug therapy; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis*; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis* / Q000188:drug therapy
D014151:Anti-Anxiety Agents; D014150:Antipsychotic Agents; D001569:Benzodiazepines